These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. Nonclassical transport proteins and peptides: an alternative to classical macromolecule delivery systems. Kueltzo LA; Middaugh CR J Pharm Sci; 2003 Sep; 92(9):1754-72. PubMed ID: 12949995 [TBL] [Abstract][Full Text] [Related]
47. Bioinspired peptides as versatile nucleic acid delivery platforms. Gopal V J Control Release; 2013 May; 167(3):323-32. PubMed ID: 23474032 [TBL] [Abstract][Full Text] [Related]
48. TAT-based drug delivery system--new directions in protein delivery for new hopes? Rapoport M; Lorberboum-Galski H Expert Opin Drug Deliv; 2009 May; 6(5):453-63. PubMed ID: 19413454 [TBL] [Abstract][Full Text] [Related]
49. [Development of intelligent DDS technologies]. Okano T Nihon Rinsho; 1993 Nov; 51(11):3042-50. PubMed ID: 8277588 [TBL] [Abstract][Full Text] [Related]
50. Influence of protein transduction domains on intracellular delivery of macromolecules. Murriel CL; Dowdy SF Expert Opin Drug Deliv; 2006 Nov; 3(6):739-46. PubMed ID: 17076596 [TBL] [Abstract][Full Text] [Related]
51. Development of protein mimics for intracellular delivery. deRonde BM; Tew GN Biopolymers; 2015 Jul; 104(4):265-80. PubMed ID: 25858701 [TBL] [Abstract][Full Text] [Related]
52. Present and future of cell-penetrating peptide mediated delivery systems: "is the Trojan horse too wild to go only to Troy?". Vives E J Control Release; 2005 Dec; 109(1-3):77-85. PubMed ID: 16271792 [TBL] [Abstract][Full Text] [Related]
53. Peptide-mediated cell delivery: application in protein target validation. Lindsay MA Curr Opin Pharmacol; 2002 Oct; 2(5):587-94. PubMed ID: 12324264 [TBL] [Abstract][Full Text] [Related]
54. Insight of current technologies for oral delivery of proteins and peptides. Drug Discov Today Technol; 2012; 9(2):e71-e174. PubMed ID: 24064270 [No Abstract] [Full Text] [Related]
55. The molecular pharmacology of glucagon agonists in diabetes and obesity. Novikoff A; Müller TD Peptides; 2023 Jul; 165():171003. PubMed ID: 36997003 [TBL] [Abstract][Full Text] [Related]
56. Calcium/Calmodulin-Dependent Protein Kinase II in Cerebrovascular Diseases. Zhang X; Connelly J; Levitan ES; Sun D; Wang JQ Transl Stroke Res; 2021 Aug; 12(4):513-529. PubMed ID: 33713030 [TBL] [Abstract][Full Text] [Related]
57. Liu X; Zhang L; Jiang W; Yang Z; Gan Z; Yu C; Tao R; Chen H Drug Deliv; 2020 Dec; 27(1):599-606. PubMed ID: 32308051 [TBL] [Abstract][Full Text] [Related]
58. PCM and TAT co-modified liposome with improved myocardium delivery: in vitro and in vivo evaluations. Wang X; Huang H; Zhang L; Bai Y; Chen H Drug Deliv; 2017 Nov; 24(1):339-345. PubMed ID: 28165817 [TBL] [Abstract][Full Text] [Related]
59. Design of Stable α-Helical Peptides and Thermostable Proteins in Biotechnology and Biomedicine. Yakimov AP; Afanaseva AS; Khodorkovskiy MA; Petukhov MG Acta Naturae; 2016; 8(4):70-81. PubMed ID: 28050268 [TBL] [Abstract][Full Text] [Related]
60. Multivalent dendritic polyglycerolamine with arginine and histidine end groups for efficient siRNA transfection. Sheikhi Mehrabadi F; Zeng H; Johnson M; Schlesener C; Guan Z; Haag R Beilstein J Org Chem; 2015; 11():763-72. PubMed ID: 26124878 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]